---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-045670"
form_type: "8-K"
ticker: "RCKT"
cik: "0001281895"
company_name: "ROCKET PHARMACEUTICALS, INC."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:20:08.477097+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Rocket Pharma Q3 2024 net loss $198.4M; cash $235.7M; pipeline advances

## Summary
- Net loss $198.4M ($2.11/share) for nine months ended Sept 30, 2024, vs $185.9M ($2.30/share) prior year.
- Cash $235.7M as of Sept 30; expects runway into 2026.
- R&D expenses $133.9M (down from $144.6M); G&A $76.6M (up from $51.8M) due to commercial prep.
- Completed enrollment in Phase 2 pivotal study of RP-A501 for Danon disease; dosing ongoing.
- Initiated rolling BLA for RP-L102 for Fanconi Anemia; FDA approval for KRESLADI anticipated 2025.

## SEC filing metadata
- accession: 0001140361-24-045670
- form_type: 8-K
- ticker: RCKT
- cik: 0001281895
- company_name: ROCKET PHARMACEUTICALS, INC.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1281895/000114036124045670/0001140361-24-045670-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1281895/000114036124045670/ef20038212_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-045670
- JSON: https://secwatch.observer/filing/0001140361-24-045670.json
- Plain text: https://secwatch.observer/filing/0001140361-24-045670.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.